Kidney Week

Abstract: TH-PO265

Measuring Quality of Life in Patients with CKD Anemia – SF36 and KDQOL

Session Information

• Anemia and Iron Metabolism: Clinical
  October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

• 202 Anemia and Iron Metabolism: Clinical

Authors

• Pecoits-Filho, Roberto, Pontificia Universidade Catolica do Parana, Curitiba, Paraná, Brazil

Roberto Pecoits-Filho,

• Spinowitz, Bruce S., New York Hospital Medical Center of Queens, New Rochelle, New York, United States

Bruce S. Spinowitz,

• Pergola, Pablo E., Renal Associates, PA, San Antonio, Texas, United States

Pablo E. Pergola,

• Rochette, Samuel, Analysis Group, Inc., Montreal, Quebec, Canada

Samuel Rochette,

• Thompson-Leduc, Philippe, Analysis Group, Inc., Montreal, Quebec, Canada

Philippe Thompson-Leduc,

• Lefebvre, Patrick, Analysis Group, Inc., Montreal, Quebec, Canada

Patrick Lefebvre,

• Bozas, Ana, Akebia Therapeutics, Inc., Cambridge, Massachusetts, United States

Ana Bozas,

• Shafai, Gigi, Akebia Therapeutics, Inc., Cambridge, Massachusetts, United States

Gigi Shafai,

• Sanon, Myrlene, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, United States

Myrlene Sanon,

• Krasa, Holly, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, United States

Holly Krasa,

Background

Anemia of chronic kidney disease (CKD) has deleterious impacts on patients’ quality of life (QoL). The Standardized Outcomes in Nephrology (SONG) initiative identified QoL components as essential trial outcomes to be reported in hemodialysis and peritoneal dialysis-dependent (DD) patients. Resolving anemia of CKD may lead to more important QoL benefits in non-DD (NDD) patients than in DD patients (Eriksson 2016). QoL is frequently assessed using the 36-item general Short Form (SF-36) and the CKD-targeted Kidney Disease QoL (KDQoL), the latter being preferred in US dialysis clinics (Peipert 2017). It is unclear to which extent QoL tools are used to study anemia of CKD, and specifically in NDD patients. Therefore, we aimed to describe the evidence on treatments for anemia of CKD in which SF-36 and/or KDQoL were used, in both DD and NDD patients.

Methods

Studies included in a broader systematic literature review of treatments for anemia of CKD were reviewed. The Cochrane Library, MEDLINE, EMBASE, NHS EED, and NHS HTA were searched for English publications. Studies published between 1/1/2000-3/17/2017 meeting the following criteria were included: adult patients; focus is anemia of CKD; patients receiving iron, red blood cell transfusions, erythropoiesis-stimulating agents (ESA); results on QoL. Studies that used SF-36 or KDQoL were retained and qualitatively synthesized.

Results

1,625 publications were identified and 17 met the eligibility criteria. All studies focused on ESA, with or without iron replacement. SF-36 was used more frequently than KDQoL (11/17, 64.7%) across studies. Notably, KDQoL was used more frequently (vs. SF-36) in studies on DD patients (4 vs. 2) than in studies on NDD patients (1 vs. 8; 2 studies with mixed DD/NDD patients). Both tools showed QoL improvements (SF-36: 8/11, KDQoL: 4/6). QoL domains improved (e.g., vitality, physical/social functioning) and magnitude of results varied widely.

Conclusion

KDQoL was less frequently used in the NDD population than in DD patients (as expected, given CMS guidelines). Findings highlight how QoL treatment benefits are variable, and that there is a lack of standardized use of adapted QoL tools in studies of NDD patients.

Funding

• Commercial Support – Akebia Therapeutics, Inc.